Shionogi acquires Maze Therapeutics' Pompe disease program, MZE001, in an exclusive global licensing agreement.
Shionogi acquires Maze Therapeutics' Pompe disease program, MZE001, in an exclusive global licensing agreement. MZE001 is an oral glycogen synthase 1 (GYS1) inhibitor that may become the first oral therapy for Pompe disease. Shionogi grants Maze an upfront payment of $150 million, with additional milestone payments and tiered royalties on future net sales. The US FDA granted orphan drug designation to MZE001 in 2022.
May 10, 2024
5 Articles